The research-based pharmaceutical industry has faced growing challenges in recent years as a result of increased economic and regulatory pressures leading to a need of accelerating drug discovery and development processes.
A good management of preclinical studies will allow to shorten development timelines and to obtain earlier clinical data for your lead candidate.
By combining its expertise in both preclinical and clinical studies, Forenap Pharma will optimise the preclinical/clinical interface in order to initiate Phase I studies in the best conditions.
Our way to manage preclinical studies and our capabilities to anticipate clinical trials will provide you a flow of information throughout the preclinical development and will speed up the coming of your drug to the later stage of its clinical development in the best conditions.
To speed-up preclinical development
- One single partner from discovery to clinical program
Screening and exploratory studies (Central Nervous System)
API synthesis
Safety Pharmacology
Toxicology
Genotoxicity
Metabolism
Analytics
IMPs
Submission documents (IMPD, IB…)
- Direct access to a well set-up international network of experts in preclinical and clinical development
- A broad network of partners has been set up and covers all areas needed for a full non-clinical development of your compound. A good insight of this network allows us to use the skills of each partner at their best.
Preclinical development optimization
- Development of individual and integrated solutions
- Proposal of preclinical and/or clinical development plans (studies design, planning and quotations)
- Set-up and follow-up of preclinical studies
- Review of the preclinical data, required for human trials initiation
- Anticipation to prepare submission documents for clinical purpose (IMPD, IB…)
